Evidence map›Paper›PMID 33762580›Full record

ArticleCell death & disease2021

Circ-HMGA2 (hsa_circ_0027446) promotes the metastasis and epithelial-mesenchymal transition of lung adenocarcinoma cells through the miR-1236-3p/ZEB1 axis.

Zhongjian Yu, Xiongjie Zhu, Ying Li, Min Liang, Meijun Liu, Zhile Liu, Lingyu Qin, Xiaoran Wu, Kunpeng Du, Lu Liu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The emerging role and mechanism of HMGA2 in breast cancer.Journal of cancer research and clinical oncology · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Zhongjian Yu *Medical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-5591-6425
Xiongjie Zhu *Medical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Ying LiDepartment of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Min LiangDepartment of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Meijun LiuMedical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Zhile LiuDepartment of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Lingyu QinDepartment of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Xiaoran WuDepartment of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Kunpeng DuMedical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Lu LiuMedical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Yong WangDepartment of Medical Oncology, First Affiliated Hospital of Nanchang University, Nanchang, China. 1529845162@qq.com.
Yanfang ZhengMedical Oncology Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China. 18665000236@163.com.
Guangzhou Medical University · CNZhujiang Hospital · CNGuangzhou Medical University Cancer Hospital · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) has high incidence and mortality rates worldwide; however, its detailed molecular pathology remains unclear. Although circRNAs have gradually been identified as molecules that are differentially expressed in tumors and play key roles in tumor progression, their role in LUAD is poorly understood. Through microarray analysis, we obtained the circRNA expression profile of LUAD and found that circ-HMGA2 (hsa_circ_0027446), a novel RNA, is highly expressed in LUAD. The high expression of circ-HMGA2 was further verified in 36 paired LUAD and adjacent normal tissues. Functionally, circ-HMGA2 promoted LUAD cell metastasis in vitro and in vivo. The luciferase reporter assay and FISH results showed that circ-HMGA2 interacts with miR-1236-3p and that miR-1236-3p interacts with ZEB1. In addition, miR-1236-3p was expressed at low levels in LUAD, inhibited LUAD cell metastasis, and suppressed the function of circ-HMGA2. ZEB1 is an EMT-promoting transcription factor. The PCR and WB analysis results showed that circ-HMGA2 promotes both ZEB1 expression and EMT. MiR-1236-3p had the opposite effect, reversing the promotive effect of circ-HMGA2 on EMT. In summary, circ-HMGA2 promotes LUAD cell metastasis through the miR-1236-3p/EMT axis, indicating that it could be a therapeutic target in LUAD.

Indexed as

Adenocarcinoma of LungAnimalsCell Line, TumorDisease ProgressionEpithelial-Mesenchymal TransitionHumansLung NeoplasmsMiceMice, NudeNeoplasm MetastasisRNA, CircularZinc Finger E-box-Binding Homeobox 1RNA, CircularZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID33762580
PMCPMC7991034
OpenAlexW3139409031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.